Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News

Prospect Venture Partners

Home
Team
Russell Hirsch
David Schnell
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News
David Schnell
May 20, 2019

May 20, 2019 - New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® in Patients with Refractory MAC Lung Disease

David Schnell
May 20, 2019

Source:http://investor.insmed.com/2019-05-20-New-Phase-3-Data-Show-Sustainability-and-Durability-of-Culture-Conversion-with-ARIKAYCE-R-amikacin-liposome-inhalation-suspension-in-Patients-with-Refractory-MAC-Lung-Disease

Newer PostJune 5, 2019 - NGM Bio to Present New Data from Phase 1b Study of NGM313 at the American Diabetes Association
Older PostMay 9, 2019 - NinePoint Medical Announces Publication of 1000 Patient Registry Study

Contact Prospect
Venture Partners:

Address:
525 University Ave., Suite 1350
Palo Alto, CA 94301

Phone:
(650) 327-8800

Prospect Ventures Funds:
Prospect Venture Partners I
Prospect Venture Partners II
Prospect Venture Partners III

 Connect with Prospect Ventures:
 Prospect Ventures on LinkedIn
 Prospect Ventures on Crunchbase
 Prospect Ventures on Bloomberg
 Prospect Ventures on CB Insights
 Prospect Ventures on Palico
 Prospect Ventures on Index.co
 Prospect Bio Ventures

Back to Top

© 2018 - Prospect Venture Partners.. All Rights Reserved
No content on this site may be republished or reprinted without written permission from Prospect Venture Partners